BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes. The company is presenting the posters at the 7th Bradykinin Symposium in Berlin from September 5-6, 2024. APeX-N interim results: Oral berotralstat for HAE prophylaxis in EuropeHCP and patient perspectives: HAE long-term prophylaxis and shared decision-making Adverse health outcomes and perspectives of androgen use in HAEEvaluation of adherence to berotralstat in patients with hereditary angioedemaTolerability and effectiveness of berotralstat for long-term prophylaxis in HAEEffectiveness and safety of berotralstat in HAE with normal C1-inhibitor APeX-N inte
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks [Financial Post (Toronto, Ontario, Canada)]Financial Post
- BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksGlobeNewswire
- BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium [Yahoo! Finance]Yahoo! Finance
- BioCryst Appoints Dr. Donald Fong Chief Medical OfficerGlobeNewswire
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BCRX
Earnings
- 8/5/24 - Beat
BCRX
Sec Filings
- 9/10/24 - Form SC
- 9/3/24 - Form 4
- 8/6/24 - Form S-8
- BCRX's page on the SEC website